Latest News - Oklahoma Society of Clinical Oncology

Clinical case studies demonstrate the performance of the Signatera™ test in cancer patients receiving immunotherapy.

SAN CARLOS, Calif., Nov. 10, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new immunotherapy data on its personalized and tumor-informed molecular residual disease (MRD) assay, Signatera, at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, taking place November 9-14, 2020.  Natera will present […]

Read More

Pfizer provides virtual resources to support OSCO members.

Pfizer Pharmaceuticals is offering the following virtual program to OSCO members.  Anyone wishing to attend should RSVP to [email protected] Speaker Topic Program Day/Date Program Start Time   Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA Biosimilars – An Overview for Health Care  Professionals Thursday, November 19, 2020 11:30 AM PT

Read More

PALTOWN and Natera team up to launch COLONTOWN University

PALTOWN Development Foundation today announced its partnership with Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, on the launch of COLONTOWN University (CTU), the first of its kind online learning center for over 5,300 Colorectal Cancer (CRC) patients and caregivers. COLONTOWN University is a secure online platform that hosts training and educational […]

Read More

Natera Announces Prospective Randomized Clinical Trial with Signatera™

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced that its Signatera molecular residual disease (MRD) test will be used in the DARE study, a multi-center clinical trial of palbociclib (IBRANCE®), a CDK4/6 inhibitor developed by Pfizer for the treatment of HR-positive, HER2-negative advanced breast cancer when given in combination with an aromatase […]

Read More

Lilly, USA announces Thyroid Cancer Testing Program for thyroid cancer patients.

Lilly’s Thyroid Cancer Testing Program is designed to provide access to molecular testing for appropriate advanced or metastatic medullary thyroid cancer (“MTC”) patients 12 years of age and older who require systemic therapy and advanced or metastatic non-medullary thyroid cancer (“non-MTC”) patients 12 years of age and older who are radioactive iodine-refractory (if radioactive iodine […]

Read More

Medicare Issues Draft Local Coverage Determination for Signatera™

Medicare Issues Draft Local Coverage Determination for Signatera™ in Immunotherapy Response Monitoring. Proposes expanded coverage of the Signatera minimal residual disease (MRD) test in a broad range of solid tumor types and indications including immunotherapy (IO) monitoring. Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the CMS Molecular Diagnostics […]

Read More

Medicare Reimbursement Update for CAR-T Finalized

On September 2, the Centers for Medicare & Medicaid Services (CMS) released updates to the Inpatient Prospective Payment System (IPPS) final rule for fiscal year 2021, including updates to Medicare payment policies and payment rates for most acute care hospitals.CMS finalized its proposal to establish a Medicare Severity Diagnosis Related Group (MSDRG) for chimeric antigen […]

Read More

Natera Receives Final Medicare Coverage for its Signatera™ MRD Test in Stage II-III Colorectal Cancer – Creates patient access to first-of-its-kind, personalized ctDNA test

SAN CARLOS, Calif., Sept. 3, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the CMS Molecular Diagnostics Program (MOLDX) has finalized a local coverage determination (LCD) to provide Medicare benefits for serial use of the Signatera molecular residual disease (MRD) test in patients with stage II or III […]

Read More

CMS Releases Physician Fee Schedule Proposed Rule

On August 3, the Centers for Medicare and Medicaid Services (CMS) released the CY 2021 Physician Fee Schedule proposed rule.  CMS is not proposing any changes to the values of the outpatient evaluation and management (E/M) services finalized in the CY 2020 rulemaking. If this rule is finalized as proposed, hematology/oncology is projected to see […]

Read More

Merck Announces Status Indicator Update from CMS

Merck announced that CMS has made a status indicator change regarding ONTRUZANT®(trastuzumab-dttb), for injection, for intravenous use 21 mg/mL, which has a Q-code of Q5112.  As of July 2020, Centers for Medicare & Medicaid Services (CMS) has issued a Corrected Addendum B to update the non-payable status for ONTRUZANT (Q5112) to Status Indicator “K”, which […]

Read More